ABI-6250

DRUG2 trials

Sponsors

Assembly Biosciences

Conditions

Chronic Hepatitis D InfectionHepatitis DHepatitis Delta Virus

Phase 1

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants

CompletedNCT06740474

Assembly BiosciencesHepatitis D, Hepatitis Delta Virus

Start: 2025-01-31End: 2025-07-08Updated: 2025-12-04

Phase 2

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection

Not yet recruitingNCT07762027

Assembly BiosciencesChronic Hepatitis D Infection

Start: 2026-10-01End: 2028-09-01Target: 80Updated: 2026-08-13